New Onset of Uveitis During Anti-Tumor Necrosis Factor Treatment for Rheumatic Diseases

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 3, 2011, Pages 503-510

  Wendling, Daniel ^a   Paccou, Julien ^b   Berthelot, Jean Marie ^c   Flipo, René Marc ^b   Guillaume Czitrom, Séverine ^d   Prati, Clément ^a   Dernis, Emmanuelle ^e   Direz, Guillaume ^f   Ferrazzi, Véronique ^g   Ristori, Jean Michel ^h  

^a Centre Hospitalier Universitaire ^*  (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e CENTRE HOSPITALIER   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Anti TNF therapy; Paradoxical effect; Uveitis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CHILD; CLINICAL ARTICLE; DATA ANALYSIS; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MEDICAL SPECIALIST; MEDLINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REGISTER; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; UVEITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 82955195759     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.05.005     Document Type: Article

References (39)

1. Zeboulon N., Dougados M., Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008, 67(7):955-959.
2. Kotaniemi K., Kautiainen H., Karma A., Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 2001, 108:2071-2075.
3. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91(3):319-322.
4. Sharma S.M., Nestel A.R., Lee R.W., Dick A.D. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009, 17(6):403-414.
5. Guignard S., Gossec L., Salliot C., Ruyssen-Witrand A., Luc M., Duclos M., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006, 65(12):1631-1634.
6. Hale S., Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006, 33(4):231-237.
7. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45(8):982-989.
8. Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52(8):2447-2451.
9. Sieper J., Koenig A., Baumgartner S., Wishneski C., Foehl J., Vlahos B., et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010, 69(1):226-229.
10. Rudwaleit M., Rødevand E., Holck P., Vanhoof J., Kron M., Kary S., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68(5):696-701.
11. Cobo-Ibáñez T., del Carmen Ordóñez M., Muñoz-Fernández S., Madero-Prado R., Martín-Mola E. Do TNF-blockers reduce or induce uveitis?. Rheumatology (Oxford) 2008, 47(5):731-732.
12. Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis?. A registry-based study. Arthritis Rheum 2007, 56(10):3248-3252.
13. Fouache D., Goëb V., Massy-Guillemant N., Avenel G., Bacquet-Deschryver H., Kozyreff-Meurice M., et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009, 48(7):761-764.
14. Taban M., Dupps W.J., Mandell B., Perez V.L. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006, 14(3):145-150.
15. Wang F., Wang N.S. Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol 2009, 27(5):838-839.
16. Saurenmann R.K., Levin A.V., Feldman B.M., Laxer R.M., Schneider R., Silverman E.D. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006, 149(6):833-836.
17. Kakkassery V., Mergler S., Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis?. Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010, 35(8):751-756.
18. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45(3):252-257.
19. Tiliakos A.N., Tiliakos N.A. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?. J Rheumatol 2003, 30(12):2727.
20. Coates L.C., McGonagle D.G., Bennett A.N., Emery P., Marzo-Ortega H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008, 67(5):729-730.
21. Reddy A.R., Backhouse O.C. Does etanercept induce uveitis?. Br J Ophthalmol 2003, 87(7):925.
22. Kaipiainen-Seppänen O., Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003, 62(1):88-89.
23. Rosenbaum J.T. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004, 50(11):3736-3737.
24. Schmeling H., Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005, 44(8):1008-1011.
25. Scrivo R., Spadaro A., Spinelli F.R., Valesini G. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008, 58(5):1555-1556. author reply 1556-7.
26. Galor A., Perez V.L., Hammel J.P., Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113(12):2317-2323.
27. Johnsen-Soriano S., Sancho-Tello M., Arnal E., Díaz-Llopis M., Navea A., Miranda M., et al. Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model. Ocul Immunol Inflamm 2010, 18(3):208-215.
28. Ozdal P.C., Vianna R.N., Deschenes J. Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults. Ocul Immunol Inflamm 2005, 13:33-38.
29. Richards J.C., Tay-Kearney M.L., Murray K., Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005, 33:461-468.
30. Vazquez-Cobian L.B., Flynn T., Lehman T. Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149:572-575.
31. Tynjala P., Kotaniemi K., Lindahl P. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008, 47:339-344.
32. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B., et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007, 34:1146-1150.
33. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
34. Tynjala P., Lindahl P., Honkanen V., Lahdenne P., Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548-550.
35. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor-a inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982-989.
36. Monnet D., Moachon L., Dougados M., Brezin A.P. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006, 2:393-397.
37. Martín-Mola E., Sieper J., Leirisalo-Repo M., Dijkmans B.A., Vlahos B., Pedersen R., et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010, 28:238-245.
38. Salmon-Ceron D., Tubach F., Lortholary O., Chosidow O., Bretagne S., Nicolas N., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70:616-623.
39. Baeten D., van Hagen P.M. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?. Ann Rheum Dis 2010, 69:2067-2073.